Exon skipping is a potential treatment approach for correcting and restoring production of dystrophin.
For specific genetic mutations, it allows the body to make a shorter, usable dystrophin. Exon skipping is not a cure for Duchenne, but it may make the effects less severe. No single drug will help everyone with Duchenne. The most common mutation amenable to exon skipping is exon 51, which only affects 13% of all patients. But doctors believe that 60-80% of Duchenne patients may eventually benefit from exon skipping.